Buradasınız

Anasayfa » Content

Orta ve yüksek malignite eğilimli tedavi edilmemiş non-Hodgkin lenfomalarda MİNE protokolü uygulaması

Administration of MINE Protocol in Untreated Patients with Intermediate and High Grade Non-Hodgkin's Lymphoma

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1997

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In recent years, more effective and less toxic treatment protocols have been developed to rise cure rates in intermediate and high grade non-Hodgkin's lymphoma (NHL). This study was undertaken to investigate the efficacy and toxicity of MINE (ifosfamide, mesna, mitoxantrone and etoposide) combination chemotherapy in patients with intermediate and high grade non-Hodgkin's lymphoma. Twenty-one patients (16 male, 5 female; aged between 26 and 70 years) with non-Hodgkin's lymphoma were included in the study. An overall response rate of 73% and complete response rate of 56% were achieved and survival rate for responding patients was 80% at 48th month. Side effects including mild myelosuppression, nausea-vomiting, and alopecia were observed. MINE combination seems to be effective and well tolerated without significant toxicity as a first-line therapy in patients with intermediate or high grade NHL. [Journal of Turgut Özal Medical Center 1997;4(1):59-62]
Bookmark/Search this post with
Abstract (Original Language): 
Son yıllarda, orta ve yüksek malignite eğilimli non-Hodgkin lenfomalarda (NHL) etkili ve az toksik olan kemoterapi protokolleri kür oranını artırmak amacı ile geliştirilmiştir. Bu çalışma MİNE protokolünün NHL'daki etkinliğini araştırmak amacı ile yapılmıştır. Çalışmaya 16'sı erkek, 5'i kadın olmak üzere, yaşları 26-70 arasında değişen toplam 21 hasta alınmıştır. Hastaların %56'sında tam remisyon elde edilmiş olup, objektif yanıt %73 idi. Tedavi sırasında ılımlı myelosupresyon, bulantı, kusma ve alopesi dışında önemli ağırlıkta yan etki gözlenmedi. Bu çalışma NHL 'da MİNE protokolünün, önemli bir yan etkisi olmaksızın, etkili olabilecek bir tedavi seçeneği oluşturduğunu göstermektedir. [Turgut Özal Tıp Merkezi Dergisi 1997;4(1):59-62]
FULL TEXT (PDF): 
PDF icon arastirmax-orta-yuksek-malignite-egilimli-tedavi-edilmemis-non-hodgkin-lenfomalarda-mine-protokolu-uygulamasi.pdf
  • 1
59-62
  • Turkish

REFERENCES

References: 

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023-30.
2. DeLena M, Ditonno P, Lorusso V, et al. CEOP-B alternated with VIBM in intermediate-grade and high grade non-Hodgkin's lymphoma: A pilot study. J Clin Oncol 1995;
13:953-60.
3. Rodriguez V, McCredie KB, Keating M, Valdivieso M, Bodey GP, Freireich EJ. Ifosfamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat Rep 1978;62: 493-7.
4. Gams RA, Steinberg J, Posner L. Mitoxantrone in malignant lymphoma. Semin Oncol 1984;11(Suppl 1): 47-9.
5. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of salvage treatment program for relapsing lymphoma:
MINE consolidated with ESHAP. J Clin Oncol 1995;13:1734-41.
6. WHO handbook for reporting results of cancer treatment, WHO offset publication no. 48, Switzerland: World Health Organization, 1979.
7. Skarin AT. Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphomas. Semin Oncol 1986;13(Suppl
5): 10-25.
8. De Vita VT Jr, Jaffe ES, Mauch P, Longo DL. Lymphocytic
lymphomas. In: De Vita V T Jr., Helmann S, Rosenberg S A, eds. Cancer principles and practice of oncology. 3rd ed.
Philadelphia: Lippincott, 1989: 1741-98.
9. Jagannath S, Velasquez WS, Tucker S, et al. Stage IV diffuse large-cell lymphoma: A long term analysis. J Clin
Oncol 1985;3:39-47.
10. Fisher RI, De Vita VT, Hubbard SM, et al. Diffuse
aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP therapy. Ann
Intern Med 1983; 98: 304-9.
11. Klimo P, Connors JM. MACOP-B chemotherapy for the
treatment of diffuse large cell lymphoma. Ann Intern Med
1985; 102: 596-602.
12. Laurence J, Coleman M, Allen SL, Silver RT, Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with six-drug COP-BLAM regimen. Ann Intern Med 1982; 97: 190-5.
13. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J
Med 1993; 328: 1002-6.
14. Herbrecht R, Coiffier B, Tilly H, et al. Mitoxantrone,
ifosfamide and etoposide(MIV) in aggressive lymphomas failing after treatment with the LNH 87 regimen(abstract). 27th Annual Meeting of the American Society of Clinical
Oncology, Houston-USA 1991; 968.
15. Ozisik Y, Kars A, Barista I, Tekuzman G, Kansu E, Firat D. The role of bleomycin, cyclophosphamide, mitoxantrone, vincristine and prednisone(BCNOP) in non-Hodgkin's lymphoma. Turk J Cancer 1994; 24: 20-7.
16. Lorusso V, Brandi M, Paradiso A, DeLena M. Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphoma(NHL).25th Annual Meeting of the American Society of Clinical Oncology, San Francisco-USA 1989;
1030.
17. Tigaud JD, Demolombe S, Bastion Y, Bryon PA, Coiffier B. Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: A phase II study. Hematological Oncology 1991; 9: 225-33.

Thank you for copying data from http://www.arastirmax.com